Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Deferred Taxes (2016 - 2024)

Historic Deferred Taxes for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q4 2024 value amounting to $109000.0.

  • Lifecore Biomedical, Inc. \De\'s Deferred Taxes rose 37250.0% to $109000.0 in Q4 2024 from the same period last year, while for Nov 2024 it was $136000.0, marking a year-over-year decrease of 6650.25%. This contributed to the annual value of $163000.0 for FY2024, which is 5434.17% down from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Deferred Taxes of $109000.0 as of Q4 2024, which was up 37250.0% from -$100000.0 recorded in Q3 2024.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Deferred Taxes ranged from a high of $2.4 million in Q2 2020 and a low of -$5.3 million during Q1 2020
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Deferred Taxes had a median value of -$82000.0 in 2024 and averaged -$849300.0.
  • The largest annual percentage gain for Lifecore Biomedical, Inc. \De\'s Deferred Taxes in the last 5 years was 55972.97% (2020), contrasted with its biggest fall of 177420.38% (2020).
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Deferred Taxes stood at -$2.4 million in 2020, then decreased by 17.58% to -$2.8 million in 2021, then surged by 100.14% to $4000.0 in 2022, then crashed by 1100.0% to -$40000.0 in 2023, then soared by 372.5% to $109000.0 in 2024.
  • Its Deferred Taxes stands at $109000.0 for Q4 2024, versus -$100000.0 for Q3 2024 and -$64000.0 for Q2 2024.